Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rotavirus vaccine - GlaxoSmithKline

Drug Profile

Rotavirus vaccine - GlaxoSmithKline

Alternative Names: 89-12; GSK 444563; GSK Biologicals' liquid human rotavirus vaccine 444563; GSK rotavirus vaccine 444563; GSK vaccine 444563; HRV Liquid - GlaxoSmithKline; HRV Lyophilized - GlaxoSmithKline; RIX-4414; Rotarix; Rotavirus vaccine - AVANT Immunotherapeutics/GlaxoSmithKline; Rotavirus vaccine 444563 - GlaxoSmithKline; SB-444563

Latest Information Update: 03 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AVANT Immunotherapeutics; Cincinnati Childrens Hospital Medical Center
  • Developer GlaxoSmithKline; Japan Vaccine
  • Class Attenuated vaccines; Rotavirus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Rotavirus infections

Most Recent Events

  • 19 Jul 2019 Phase-III clinical trials in Rotavirus infections (In infants, Prevention) in Hong Kong, Turkey, Canada (PO) (NCT03954743)
  • 19 Jul 2019 GlaxoSmithKline initiates a phase III trial in Rotavirus infections (In infants, Prevention) in USA and Taiwan (PO) (NCT03954743)
  • 17 May 2019 GlaxoSmithKline plans a phase III trial for Rotavirus infections (In infants, Prevention) in Canada, Hong Kong, Taiwan, Turkey, and USA (PO, Liquid, Lyophilised) in July 2019 (NCT03954743)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top